Epoprostenol in pulmonary arterial hypertension

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 1, 2009, Pages 83-90

  Jacobs, Wouter ^a   Vonk Noordegraaf, Anton ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epoprostenol; Prostacyclin; Prostanoid; Pulmonary arterial hypertension; Review

Indexed keywords

BERAPROST; BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL; UNIPROST; DRUG DERIVATIVE; PROSTACYCLIN DERIVATIVE;

CLINICAL TRIAL; CONTINUOUS INFUSION; DEATH; DISEASE COURSE; DRUG COST; DRUG USE; EXERCISE; FLUSHING; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERTHYROIDISM; INFUSION PUMP; JAW DISEASE; LOOSE FECES; LUNG HEMODYNAMICS; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SURVIVAL; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG CONTROL; DRUG THERAPY; ECONOMICS; TREATMENT OUTCOME;

ANIMALIA;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; DRUG THERAPY; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PROSTAGLANDINS I; TREATMENT OUTCOME;

EID: 66449128233     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250802622962     Document Type: Review

References (106)

1. Klob . Wien Wochenbl 1865;31:45
2. Romberg E. Über sklerose der lungen arterie. Dtsch Arch Klin Med 1891;48:197-206
3. Abenhaim L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-616
4. Group IPPHS: The international primary pulmonary hypertension study. Chest 1994;105:S37-41
5. Appelbaum L, Yigla M, Bendayan D, et al. Primary pulmonary hypertension in Israel: a national survey. Chest 2001;119:1801-1806
6. Mac Gregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001;40:453-459
7. Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997;24:81-85
8. Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest 1997;111:36-43
9. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-993
10. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65-74
11. Yamane K, Ihn H, Asano Y, et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology (Oxford) 2000;39:1269-1271
12. Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62:146-150
13. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000;9:338-342
14. Asherson RA, Higenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990;17:1292-1298
15. Alpert MA, Goldberg SH, Singsen BH, et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 1983;68:1182
16. Hosoda Y, Suzuki Y, Takano M, et al. Mixed connective tissue disease with pulmonary hypertension: a clinical and pathological study. J Rheumatol 1987;14:826-830
17. Nunes H, Humbert M, Sitbon O, et al. Prognostic Factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433
18. Humbert M, Nunes H, Sitbon O, et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001;22:459-475
19. Humbert M, Sitbon O, Simmoneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436
20. Gryglewski RJ. Prostaglandins, platelets, and atherosclerosis. CRC Crit Rev Biochem 1980;7:291-338
21. Badesch DB, Abman SH, Simmonneau G, et al. Medical therapy for pulmonary arterial hypertension. Updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928
22. Mc Laughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-1482
23. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788
24. Barst R, Berman-Rosenzweig E, Horn E, et al. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. Morb Mortal Wkly Rep 2007;56(8):170-172
25. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31:891-901
26. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-665
27. Bunting S, Gryglewski R, Moncada S, et al. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and celiac arteries and inhibits platelet aggregation. Prostaglandins 1976;12:897-913
28. Moncada S, Herman AG, Higgs EA, et al. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the antithrombotic properties of vascular endothelium. Thromb Res 1977;11:323-344
29. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev 1979;30:293-331
30. Utaba FB, Moncada S, Vane JR. The effect of prostacyclin (PGI2) on platelet behaviour, thrombus formation in vivo and bleeding time. Thromb Haemost 1979;41:425-435
31. Aiken JW, Gorman RR, Shebuski RJ. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 1979;17:483-494
32. Szczeklik A, Gryglewski RJ, Nizankowski R, et al. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. Pharmacol Res Commun 1978;10:545-556
33. Whittle BJR. Role of prostaglandins in the defense of the gastric mucosa. Brain Res Bull 1980;5(Suppl 1):7-14
34. Moncada S, Vane JR. The prostacyclin/thromboxane balance and cardiovascular disease. In: Isselbacher KJ. Symposium celebrating the Harvard Medical School bicentennial. New York: John Wiley & sons; 1982:83-113
35. Vane JR. Clinical potential of prostacyclin. Adv Prostaglandins Thromboxane Leukot Res 1983;11:449-456
36. Demling RH, Smith M, Gunther R, et al. The effect of prostacyclin infusions on endotoxin-induced lung injury. Surgery 1981;89:257-263
37. Araki H, Lefer AM. Cytoprotective actions of prostacyclin during hypoxia in isolated perfused cat liver. Am J Physiol 1980;238(Suppl):H176-81
38. Jugdutt BF, Hutchins GM, Bulkley BH, et al. Infarct size reduction by prostacyclin after coronary artery occlusion in conscious dogs. Clin Res 1979;27:177A
39. Ogletree ML, Lefer AM, Smith JB, et al. Studies on the cytoprotective effect of prostacyclin in acute myocardial ischaemia. Eur J Pharmacol 1979;56:95-103
40. Ribeiro LGT, Brandon TA, Hopkins DG, et al. Prostacyclin in experimental myocardial ischaemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am J Cardiol 1981;47:835-840
41. Starnes VA, Primm RK, Woosley RL, et al. Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs. J Cardiovasc Pharmacol 1982;4:765-769
42. Ohlendorf R, Perzborn E, Schrör K. Prevention of infarction-induced decrease in circulating platelet count by prostacyclin. Thromb Res 1980;19:447-453
43. Olschewski H, Olschewski A, Rose F, et al. Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 2001;138:287-297
44. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle cell proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26;194-201
45. Chow KB, Jones RL, Wise H. Protein kinase A-dependent coupling of mouse prostacyclin receptors to Gi is cell-type dependent Eur J Pharmacol 2003;474:7-13
46. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000;1483:285-293
47. Bhattacharya M, Peri K, Ribeiro-Da-Silva A, et al. Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem 1999;274:15719-15724
48. Bhattacharya M, Peri KG, Almazan G, et al. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 1998;95:15792-15797
49. Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 2000;97:13275-13280
50. Hatae T, Wada M, Yokoyama C, et al. Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem 2001;276:46260-46267
51. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997;94:4318-4323
52. Lazennec G, Canaple L, Saugy D, Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol Endocrinol 2000;14:1962-1975
53. Gray JP, Burns KA, Leas TL, et al. Regulation of peroxisome proliferator-activated receptor alpha by protein kinase C. Biochemistry 2005;44:10313-10321
54. Christman BW. Lipid mediator dysregulation in primary pulmonary hypertension Chest 1998;114(Suppl 3):205S-7S
55. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-75
56. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-1932
57. Geraci MW, Gao B, Sheperd DC, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999;103(11):1509-1515
58. Tahara N, Kai H, Niiyama H, et al. Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum Gene Ther 2004;15(12):1270-1278
59. Rich S, McLaughlin V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184-1187
60. Schermuly RT, Pullamsetti SS, Breitenbach SC, et al. Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res 2007;8:4
61. 18F] fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol 2005;45:1849-1855
62. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-1486
63. Kerbaul F, Brimioulle S, Rondelet B, et al. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med 2007;175:846-850
64. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184-1187
65. Wauthy P, Abdel KafiS, Mooi WJ, et al. Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension. J Thorac Cardiovasc Surg 2003;126:1434-1441
66. Sakuma M, Demachi J, Nawata J, et al. Epoprostenol infusion therapy changes angiographic findings of pulmonary arteries in patients with idiopathic pulmonary arterial hypertension. Circ J 2008;72:1147-1151
67. Pola R, Gaetani E, Flex A, et al. Comparative analysis of in vivo angiogenic properties of stable prostacyclin analogues: A possible role for peroxisome proliferator - activated receptors. J Mol Cell Cardiol 2004;36:363-370
68. Miyahara Y, Ohnishi S, Obata H, et al. Beraprost sodium enhances neovascularisation in ischaemic myocardium by mobilizing bone marrow cells in rats. Biochem Biophys Res Commun 2006;349:1242-1249
69. Herner SJ, Mauro LS. Epoprostenol in primary pulmonary hypertension. Ann Pharmacother 1999;33:340-347
70. Brash AR, Jackson EK, Saggese CA, et al. Metabolic dispostion of prostacyclin in humans. J Pharmacol Exp Ther 1983;226:78-87
71. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-1047
72. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). Br Heart J 1987;57:270-278
73. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomised trial. Ann Intern Med 1990;112:485-491
74. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health registry on primary pulmonary hypertension. Am Rev Respir Dis 1989;140:1623-1630
75. Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66:334-338
76. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-415
77. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302
78. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788
79. Robbins IM, Christman BW, Newman JH, et al. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 1998;114:1269-1275
80. Conte JV, Gaine SP, Orens JB, et al. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998;17:679-685
81. Badesch DB, Tapson VF, Mc Goon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-434
82. Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999;13:1351-1356
83. Klings ES, Hill NS, Ieong MH, et al. Systemic sclerosis associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999;42:2638-2645
84. Mc Laughlin VV, Genther DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999;130:740-743
85. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-1865
86. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162:1846-1850
87. Krowka MJ, Swanson KL. How should we treat portopulmonary hypertension? Eur Respir J 2006;28:466-467
88. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-2125
89. Simonneau G, Barst RJ, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804
90. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129:1636-1643
91. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28(6):1195-1203 [Epub 9 Aug 2006]
92. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329
93. Mc Laughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-1263
94. Voswinckel R, Enke B, Reichenberger F, et al. Favourable effects of inhaled treprostinil in severe pulmonary hypertension. J Am Coll Cardiol 2006;48:1672-1681
95. Higenbottam TW, Butt AY, Dinh-Xuan AT, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998;79:175-179
96. Ewert R, Opitz CF, Wensel R, et al. Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol 2007;96:211-217
97. Tapson VF, Gomberg-Maitland M, Mc Laughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective multicentre open label 12 week trial. Chest 2006;129:683-688
98. Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-1502
99. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-359
100. Simonneau G, Burgess G, Collings L, et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;3:A58
101. Simonneau G, Rubin LJ, Galiè N, et al. Safety and efficacy of sildenafil-epoprostenol combination therapy in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2007;175:A300
102. Abid F, Delgado O, Rahaghi FF. A cost analysis of the treatment of pulmonary arterial hypertension. Chest 2007;132:632S
103. Narine L, Hague LK, Walker JH, et al. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension, Curr Med Res Opin 2005;21(12):2007-2016
104. Einarson TR, Granton JT, Vincente C, et al. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Can Respir J 2005;12(8):419-425
105. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idipathic pulmonary arterial hypertension. Eur Respir J 2004;24:1007-1010
106. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007;29:469-475